Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NATR with free AI briefings, catalyst countdowns, and dilution alerts.

NATR · NATURES SUNSHINE PRODUCTS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$89.4M Cash on Hand
CF+ Cash Runway
Follow NATR by email Get an email when NATR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NATR, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NATR holds $89.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NATR files for a raise →

👥 Who Owns NATR

Insiders 17.9% Institutions (217 holders) 82.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C
10% owner
Insider 2,236,152 12.90% 2026-11-05
Kenneth G. Romanzi
Chief Executive Officer, Director
Insider 128,978 0.74% 2026-11-04
Leslie Shane Jones
EVP & Chief Financial Officer
Insider 104,658 0.60% 2026-05-05
Bryant J Yates
EVP & President, Europe
Insider 79,114 0.46% 2026-11-04
Ruth Ann Perkins
EVP, Chief Financial Officer
Insider 75,433 0.44% 2026-09-02
Robert D Straus
Director
Insider 56,514 0.33% 2026-05-15
Jonathan David Lanoy
SVP, Chief Accounting Officer
Insider 56,360 0.33% 2026-11-04
Daniel C Norman
EVP & President, Asia
Insider 48,944 0.28% 2026-11-04
Kevin R. Herbert
EVP & President, North America
Insider 46,890 0.27% 2026-06-26
Nathan G Brower
EVP, General Counsel
Insider 44,811 0.26% 2026-11-04
Heidi Wissmiller
Director
Insider 41,667 0.24% 2026-05-15
Rong Yang
Director
Insider 34,749 0.20% 2026-05-15

Share count 17,328,776 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NATR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NATR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.